Zobrazeno 21 - 30
of 79
pro vyhledávání: '"Yasuhiro Hisanaga"'
Autor:
Akira Kanamori, Toshifumi Tada, Yasuhiro Hisanaga, Takeshi Hiramatsu, Masashi Fujimori, Takashi Kumada, Hidenori Toyoda, Takanori Hosokawa, Seiki Kiriyama, Makiko Takagi, Takahiro Arakawa, Makoto Tanikawa
Publikováno v:
Journal of Clinical Virology. 47:258-262
Background The “response-guided therapy” based on response of hepatitis C virus (HCV) during antiviral combination therapy with peginterferon and ribavirin is important for patients with HCV genotype 1. However, the sensitivity of previous assays
Autor:
Takashi Kumada, Makiko Takagi, Takahiro Arakawa, Akira Kanamori, Yasuhiro Sone, Hiroyuki Atsumi, Hidenori Toyoda, Yasuhiro Hisanaga, Makoto Tanikawa, Masashi Fujimori, Seiki Kiriyama
Publikováno v:
Journal of Medical Virology. 82:539-545
The importance of alanine aminotransferase (ALT) levels in the progression of hepatitis B virus (HBV) infection remains a subject of debate. This study sought to identify independent risk factors involved in development of hepatocellular carcinoma (H
Autor:
Yasuhiro Hisanaga, Masashi Fujimori, Seiki Kiriyama, Makiko Takagi, Yasuhiro Sone, Akira Kanamori, Takashi Kumada, Takahiro Arakawa, Satoshi Nakano, Hiroyuki Atsumi, Makoto Tanikawa, Hidenori Toyoda
Publikováno v:
Journal of Hepatology. 50:729-735
This study sought to identify the independent risk factors involved in the development of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C virus (HCV) infection who have normal alanine aminotransferase (ALT) levels.A total of 519 p
Autor:
Makoto Tanikawa, Yasuhiro Hisanaga, Kazuhiko Hayashi, H. Atsumi, Hidemi Goto, Akira Kanamori, Yoshiaki Katano, S. Nakano, Takashi Honda, Takashi Kumada, H. Toyoda, T. Arakawa, Seiki Kiriyama, Y Sone
Publikováno v:
Journal of Viral Hepatitis. 15:651-658
Summary. Serum ribavirin concentration is an important factor in antiviral therapy in combination with peginterferon (PEG-IFN) and ribavirin for patients with chronic hepatitis C in terms of both beneficial and adverse effects. We evaluated whether t
Autor:
Yasuhiro Sone, Akira Kanamori, Seiki Kiriyama, Yasuhiro Hisanaga, Takashi Kumada, Hidenori Toyoda, Makoto Tanikawa
Publikováno v:
Intervirology. 50:241-244
Objectives: The effect of circulating low-level hepatitis B virus (HBV), defined as one of the states of ‘occult HBV infection’, on the development of hepatocellular carcinoma (HCC) in HBV surface antigen (HBsAg)-negative patients is controversia
Autor:
Hidenori Toyoda, Akira Kanamori, Takashi Kumada, Junko Tanaka, Shusuke Kitabatake, Yasuhiro Hisanaga, Makoto Tanikawa, Seiki Kiriyama, Toshifumi Tada, Tsuyoki Yama
Publikováno v:
Journal of gastroenterology. 51(4)
Interferon (IFN)-based therapy has been reported to reduce the liver-related mortality rate in patients with chronic hepatitis C virus (HCV) infection. However, predictors of survival and causes of death, including non-liver-related causes, have not
Autor:
Toshifumi, Tada, Takashi, Kumada, Hidenori, Toyoda, Seiki, Kiriyama, Makoto, Tanikawa, Yasuhiro, Hisanaga, Akira, Kanamori, Shusuke, Kitabatake, Tsuyoki, Yama
Publikováno v:
Journal of gastroenterology and hepatology. 30(9)
It has been reported that the branched-chain amino acid (BCAA) to tyrosine ratio (BTR) is a useful indicator of liver function and BCAA therapy is associated with a decreased incidence of hepatocellular carcinoma (HCC). However, there has not been su
Autor:
Hidenori, Toyoda, Takashi, Kumada, Toshifumi, Tada, Seiki, Kiriyama, Makoto, Tanikawa, Yasuhiro, Hisanaga, Akira, Kanamori, Shusuke, Kitabatake, Takanori, Ito
Publikováno v:
Journal of gastroenterology and hepatology. 30(7)
Hepatocellular carcinoma (HCC) can develop in patients with chronic hepatitis C after they have achieved a sustained virologic response (SVR) to antiviral therapy, that is eradication of hepatitis C virus (HCV). Thus, surveillance for HCC remains nec
Autor:
Yoichi Sato, Yoshiyuki Takagi, Hiroshi Fukui, Ryuichiro Maekawa, Takeshi Hori, Takashi Honda, Michio Sata, Akihide Hosoda, Katsuhiro Hayashi, Yuzuru Sato, Shuichi Sezai, Hirohito Tsubouchi, Kimihide Nakamura, Takashi Kumada, Yasuhiro Hisanaga, Hironaka Kawasaki, Junichi Yamao, Kazuhisa Gondo, Noboru Maetani, Yusei Ikeda, Hidetaka Matsui, Wahei Shinmura, Takuji Torimura, Masao Suzuki, Kazuhiko Oho, Satoshi Shakado, Yozo Iida, Taku Kusaba, Kouki Yutoku, Morikazu Onji, Hirofumi Fukushima, Hideaki Yamamoto, Isao Makino, Masafumi Nakayama, Hajime Watahiki, Tomoo Rikitoku, Yoshifumi Miyata, Yoshitsugu Kubo, Yayuki Hioki
Publikováno v:
Current Therapeutic Research. 67(1):1-20
Background:Many Japanese patients with hepatic disorders confirmed on diagnostic imaging and coexisting upper gastrointestinal (GI) peptic lesions receive treatment with proton pump inhibitors. Some pharmacotherapies used to treat peptic ulcers have
Autor:
Yasuhiro Sone, Masatoshi Isogai, Yasuhiro Hisanaga, Yuji Kaneoka, Akihiro Yamaguchi, Hidenori Toyoda, Seiki Kiriyama, Makoto Tanikawa, Junji Washizu, Takashi Kumada
Publikováno v:
Clinical Gastroenterology and Hepatology. 4:111-117
Background & Aims: We conducted a prospective study to evaluate the significance of simultaneous measurement of 3 currently used tumor markers in the evaluation of tumor progression and prognosis of patients with hepatocellular carcinoma (HCC). Metho